MX394355B - Método de tratamiento de meduloblastoma con un inhibidor de ezh2. - Google Patents

Método de tratamiento de meduloblastoma con un inhibidor de ezh2.

Info

Publication number
MX394355B
MX394355B MX2018004132A MX2018004132A MX394355B MX 394355 B MX394355 B MX 394355B MX 2018004132 A MX2018004132 A MX 2018004132A MX 2018004132 A MX2018004132 A MX 2018004132A MX 394355 B MX394355 B MX 394355B
Authority
MX
Mexico
Prior art keywords
meduloblastoma
treatment
ezh2 inhibitor
subject
ezh2
Prior art date
Application number
MX2018004132A
Other languages
English (en)
Other versions
MX2018004132A (es
Inventor
Heike Keilhack
Nigel J Waters
Rajeev Vibhakar
Original Assignee
Epizyme Inc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, Univ Colorado Regents filed Critical Epizyme Inc
Publication of MX2018004132A publication Critical patent/MX2018004132A/es
Publication of MX394355B publication Critical patent/MX394355B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La divulgación proporciona un método de tratamiento de un meduloblastoma en un sujeto que lo necesita, que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un potenciador de un inhibidor del homologo zeste 2 (EZH2). En una realización preferida de este método, el sujeto es pediátrico y el inhibidor de EZH2 es Tazemetostat.
MX2018004132A 2015-10-06 2016-10-05 Método de tratamiento de meduloblastoma con un inhibidor de ezh2. MX394355B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562238074P 2015-10-06 2015-10-06
US201662299312P 2016-02-24 2016-02-24
PCT/US2016/055554 WO2017062495A2 (en) 2015-10-06 2016-10-05 Method of treating medulloblastoma with an ezh2 inhibitor

Publications (2)

Publication Number Publication Date
MX2018004132A MX2018004132A (es) 2018-09-26
MX394355B true MX394355B (es) 2025-03-24

Family

ID=58488487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004132A MX394355B (es) 2015-10-06 2016-10-05 Método de tratamiento de meduloblastoma con un inhibidor de ezh2.

Country Status (12)

Country Link
US (2) US20190083504A1 (es)
EP (2) EP3371175A4 (es)
JP (1) JP7045985B2 (es)
KR (1) KR20180058829A (es)
CN (1) CN108699046A (es)
AU (3) AU2016333982A1 (es)
CA (1) CA3000983A1 (es)
EA (1) EA201890878A1 (es)
IL (2) IL258510A (es)
MX (1) MX394355B (es)
SG (1) SG10201909413SA (es)
WO (1) WO2017062495A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2887243C (en) 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
KR20180042356A (ko) 2015-08-24 2018-04-25 에피자임, 인코포레이티드 암 치료 방법
WO2017132518A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
WO2017210395A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
EP3630080A4 (en) 2017-06-02 2021-03-10 Epizyme, Inc. USE OF EZH2 INHIBITORS TO TREAT CANCER
US12178854B2 (en) 2017-07-19 2024-12-31 Children's Medical Center Corporation Compositions and methods for treating diseases associated with an imprinting defect
WO2019050924A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
EP3976044A4 (en) * 2019-06-03 2024-08-07 Icahn School of Medicine at Mount Sinai Compounds and methods for inhibiting cancers via rest inhibition
CN111905102A (zh) * 2020-09-04 2020-11-10 福建医科大学附属第一医院 Ezh2抑制剂在治疗胶质瘤中的应用
KR102821233B1 (ko) 2022-02-10 2025-06-17 서울대학교병원 Hsp70을 표적으로 하는 수모세포종 치료 및 전이 억제 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4236945A (en) * 1978-11-27 1980-12-02 Allegheny Ludlum Steel Corporation Phosphorus-iron powder and method of producing soft magnetic material therefrom
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP5864546B2 (ja) * 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インダゾール
EA023788B1 (ru) 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
JO3363B1 (ar) * 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
CA2887243C (en) * 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
CA2931263A1 (en) * 2013-12-06 2015-06-11 Epizyme, Inc. Combination therapy for treating cancer
WO2017079757A1 (en) * 2015-11-06 2017-05-11 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor

Also Published As

Publication number Publication date
CN108699046A (zh) 2018-10-23
MX2018004132A (es) 2018-09-26
US20190083504A1 (en) 2019-03-21
EA201890878A1 (ru) 2018-08-31
EP3371175A2 (en) 2018-09-12
WO2017062495A2 (en) 2017-04-13
WO2017062495A3 (en) 2017-06-08
JP2018529742A (ja) 2018-10-11
AU2016333982A1 (en) 2018-04-26
AU2023246384A1 (en) 2023-11-02
SG10201909413SA (en) 2019-11-28
US20200268765A1 (en) 2020-08-27
AU2021204331A1 (en) 2021-07-22
EP3371175A4 (en) 2019-09-25
IL281318A (en) 2021-04-29
JP7045985B2 (ja) 2022-04-01
KR20180058829A (ko) 2018-06-01
EP4309738A2 (en) 2024-01-24
IL258510A (en) 2018-05-31
CA3000983A1 (en) 2017-04-13
EP4309738A3 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
MX394355B (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
EA201790398A1 (ru) Способы лечения заболевания печени
MX2021007003A (es) Método para tratar el cáncer.
PH12015502075B1 (en) Treatment of cataplexy
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201690206A1 (ru) Терапевтически активные соединения и способы их применения
EA201791095A1 (ru) Способ лечения рака
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
MX387283B (es) Tratamiento del cancer con tg02.
MX373231B (es) Agente anticancerigeno.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
HK1256042A1 (zh) 用於治疗糖尿病周围神经病变的hdac抑制剂
MY192385A (en) Methods of treating acute kidney injury
EA201792610A1 (ru) Способ лечения неврологического заболевания
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
MY194135A (en) Treatment and diagnosis of inflammatory disorders
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2017009313A (es) Formulaciones intravenosas de baclofeno y metodos de tratamiento.
EA201891008A2 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
PH12016502284B1 (en) Cough medicine containing ambroxol hydrochloride